Reuters logo
BRIEF-Sangamo Biosciences up 13.6 percent in premarket
January 9, 2014 / 1:35 PM / in 4 years

BRIEF-Sangamo Biosciences up 13.6 percent in premarket

NEW YORK, Jan 9 (Reuters) - Sangamo BioSciences Inc : * Up 13.6 percent to $15.50 in premarket after collaboration deal with Biogen Idec to develop treatments for hemoglobinopathies

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below